Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance
Amgen reported a surprising double-digit decline for Enbrel during the first quarter and sales for the cholesterol-lowering biologic Repatha showed that the PCSK9 inhibitor is not going to make up for the company's declining revenue any time soon – at least not while payers continue to block its use.